Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (360)	3/10/1999 2:56:00 PM
From: esterina	Respond to of 2515

Another Bio stock to watch. SYBF $2 1/8 MEDIA ALERT - Pharmaceutical Industry Expert Available to Speak About Emerging Treatment For E. coli Infection Business Wire - March 10, 1999 14:37 Jump to first matched term CALGARY, Alberta--(BUSINESS WIRE)--March 10, 1999-- (NASDAQ:SYBBF) (TSE:SYB.) Comprehensive approach to fight the deadly bacteria requires prevention and treatment WHO: David Cox, Ph.D., President and CEO of SYNSORB Biotech, Inc. - More than 20 years of experience in the global biotechnology industry - Expertise in complex carbohydrate chemistry - Headquartered in Canada, SYNSORB Biotech is dedicated to accelerated drug development from the acquisition of promising compounds through clinical studies WHAT: SYNSORB Pk(R), SYNSORB Biotech's lead product currently in development for the treatment of E. coli infections - SYNSORB Pk(R) is currently being tested as a treatment for the severe complications associated with E. coli O157:H7 infections - Approximately 5 to 20 percent of children who contract E. coli infections progress to Hemolytic Uremic Syndrome (HUS), an illness that can lead to kidney failure and even death - SYNSORB Pk(r) is currently in Phase III clinical trials and continues to enroll patients in the United States, Canada and Argentina WHY: While the USDA has proposed a new rule to reduce E. coli O157:H7 and other food borne bacteria through irradiation, an emerging treatment for deadly E. coli O157:H7 infections must join the public discourse. CONTACT: For more information or to arrange a phone interview, please contact Cindy Conway at 403-270-1315 or cconway@synsorb.com CONTACT: SYNSORB Biotech Inc. Cindy Conway, 403/270-1315 cconway@synsorb.com

To: Arthur Radley who wrote (360)	3/10/1999 3:01:00 PM
From: JF2155	Read Replies (1) \| Respond to of 2515

TexasDude --I'm on it --thanks for the post JIM